A new study published by the Science Translational Medicine journal showed that, for a small cohort, LMB-100 could be even more effective when paired with Keytruda for treating patients with mesothelioma. Researchers saw a median survival rate of almost a year, with a handful of clinical trial participants continuing to show progress after more than three years.

Following this success, the National Cancer Institute is currently accepting clinical trial participants for phase 2 of the study.

LMB-100 is an immunotoxin drug designed to help the immune system find and destroy cancer and mesothelioma cells.

Keytruda, an antibody drug used in cancer immunotherapy manufactured by Merck and also known as Pembrolizumab, hasbeen approved by the FDAover the years for several treatments includingsolid tumor cancers and non-small cell lung cancer.

The study showed that patients taking both LMB-100 and Keytruda (pembrolizumab) could result in more effective treatment.

In some of the patients, receiving pembrolizumab after LMB-100 resulted in greater efficacy than what would be expected from pembrolizumab alone, said Raffit Hassan, M.D., Chief of the Thoracic and GI Malignancies Branch at the National Cancer Institute.

Patients diagnosed withmalignant mesotheliomaare encouraged to speak with their oncologist or consult with aMesothelioma Center of Excellenceto determine whether Keytruda or other medications can be an effective treatment,or whether they might be a candidate for aclinical trial. We at MesotheliomaHelp.org arealways availableto assist you.

Read more:

New Study Shows LMB-100 Can Be Even More Effective Paired with Keytruda for Mesothelioma Treatment - MesotheliomaHelp.org